Update to NCCN guidelines, is Avastin now Standard of Care in Metastic Breast Cancer?
 

If this message is not displayed correctly or to view on a mobile device, click here.http://custom.cvent.com/A534AF7FE159...1b9d6102eb.gifhttp://custom.cvent.com/A534AF7FE159...76ea472848.gif NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Breast Cancer. These NCCN Guidelines™ are currently available as Version 3.2010.
The NCCN Guidelines Panel for Breast Cancer affirmed its existing recommendation of bevacizumab in combination with paclitaxel as an appropriate therapeutic option for metastatic breast cancer with the evidence designation 2A meaning that it is based on lower level evidence and uniform agreement of the panel as to its appropriateness.
The Panel revised the related footnote, it now states: "Randomized clinical trials in metastatic breast cancer document that the addition of bevacizumab to some first or second line chemotherapy agents modestly improves time to progression and response rates but does not improve overall survival. The time to progression impact may vary among cytotoxic agents and appears greatest with bevacizumab in combination with weekly paclitaxel."
For the complete updated versions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) and NCCN Drugs & Biologics Compendium (NCCN Compendium™), please visit NCCN.org.